Cytomegalovirus infection reactivation in multiple myeloma patients administered proteasome inhibitor-combination therapy: A disproportionality analysis in a spontaneous reporting database

被引：0
|
作者：
Kaur, Gursimran [1 ]
Lukose, Lipin [1 ]
Thomas, Beulah E. [2 ]
Viswam, Subeesh Kulangara [1 ]
机构：
[1] Manipal Acad Higher Educ, Manipal Coll Pharmaceut Sci, Manipal, India
[2] Sparse Hosp, Bengaluru, Karnataka, India
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2022年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
1277
引用
收藏
页码：595 / 596
页数：2
相关论文
共 50 条
  • [41] A Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM)
    Kumar, Shaji K.
    Berdeja, Jesus G.
    Niesvizky, Ruben
    Lonial, Sagar
    Hamadani, Mehdi
    Stewart, A. Keith
    Roy, Vivek
    Hari, Parameswaran
    Vescio, Robert
    Berg, Deborah
    Lin, Jianchang
    Di Bacco, Alessandra
    Gupta, Neeraj
    Hui, Ai-Min
    Richardson, Paul G.
    BLOOD, 2012, 120 (21)
  • [42] Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study
    Kumar, Shaji K.
    Berdeja, Jesus G.
    Niesvizky, Ruben
    Lonial, Sagar
    Laubach, Jacob P.
    Hamadani, Mehdi
    Stewart, A. Keith
    Hari, Parameswaran
    Roy, Vivek
    Vescio, Robert
    Kaufman, Jonathan L.
    Berg, Deborah
    Liao, Eileen
    Di Bacco, Alessandra
    Estevam, Jose
    Gupta, Neeraj
    Hui, Ai-Min
    Rajkumar, Vincent
    Richardson, Paul G.
    LANCET ONCOLOGY, 2014, 15 (13): : 1503 - 1512
  • [43] Phase 1 Study of the Investigational Proteasome Inhibitor Ixazomib Alone or in Combination with Lenalidomide-Dexamethasone (Rd) in Japanese Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM)
    Handa, Hiroshi
    Suzuki, Kenshi
    Chou, Takaaki
    Matsushima, Takafumi
    BLOOD, 2014, 124 (21)
  • [44] Phase 1/2 Study of Oral MLN9708, A Novel, Investigational Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM)
    Berdeja, Jesus G.
    Richardson, Paul G.
    Lonial, Sagar
    Niesvizky, Ruben
    Hui, Ai-Min
    Berg, Deborah
    Gupta, Neeraj
    Liu, Guohui
    Di Bacco, Alessandra
    Kumar, Shaji
    BLOOD, 2011, 118 (21) : 223 - 223
  • [45] Neurologic adverse events associated with BRAF and MEK inhibitor therapy in patients with malignant melanoma: a disproportionality analysis using the Food and Drug Administration Adverse Event Reporting System
    Leibovit-Reiben, Zachary
    Godfrey, Hannah
    Jedlowski, Patrick
    Thiede, Rebecca
    MELANOMA RESEARCH, 2025, 35 (02) : 122 - 129
  • [46] PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma
    Koiwai, Kimiko
    El-Cheikh, Raouf
    Thai, Hoai-Thu
    Brillac, Claire
    Fau, Jean-Baptiste
    Veyrat-Follet, Christine
    Risse, Marie-Laure
    van de Velde, Helgi
    Semiond, Dorothee
    Nguyen, Laurent
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2021, 10 (08): : 928 - 940
  • [47] A systematic review and meta-analysis of randomized data on monoclonal antibodies added to proteasome inhibitor or immunomodulatory backbones in patients with relapsed and refractory multiple myeloma
    Kortuem, M.
    Schulat, C.
    Kerssenboom, R.
    Jakobs, J.
    Jensen, A.
    Mendes, J. A. D.
    Blees, A.
    Rasche, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 236 - 237
  • [48] ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM)
    Raje, Noopur
    Vogl, Dan T.
    Hari, Parameswaran N.
    Jagannath, Sundar
    Jones, Simon S.
    Supko, Jeffrey G.
    Leone, Gina
    Wheeler, Catherine
    Orlowski, Robert Z.
    Richardson, Paul G.
    Lonial, Sagar
    BLOOD, 2013, 122 (21)
  • [49] Selinexor in Combination with Bortezomib and Dexamethasone (SdB) Demonstrates Significant Activity in Patients with Refractory Multiple Myeloma (MM) Including Proteasome-Inhibitor Refractory Patients: Results of the Phase I Stomp Trial
    Bahlis, Nizar J.
    Kotb, Rami
    Sebag, Michael
    Sutherland, Heather J.
    LeBlanc, Richard
    White, Darrell
    Venner, Christopher P.
    Kouroukis, Tom
    Bergstrom, Debra
    McCurdy, Arleigh
    Lalancette, Marc
    Bensinger, William
    Lentzsch, Suzanne
    Del Col, Aldo
    Kauffman, Michael
    Shacham, Sharon
    Jeha, Jacqueline
    Picklesimer, Carla
    Saint-Martin, Jean-Richard
    Choe-Juliak, Cassandra
    Chen, Christine
    BLOOD, 2016, 128 (22)
  • [50] The HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib and Dexamethasone (NVd) Has Excellent Activity in Patients with Advanced, Proteasome Inhibitor-Refractory Multiple Myeloma: A Multicenter Phase II Trial (SAKK 39/13)
    Driessen, Christoph
    Muller, Rouven
    Novak, Urban
    Cantoni, Nathan
    Betticher, Daniel
    Mach, Nicolas
    Gregor, Michael
    Samaras, Panagiotis
    Berset, Catherine
    Rondeau, Stephanie
    Hawle, Hanne
    Hitz, Felicitas
    Pabst, Thomas
    Zander, Thilo
    BLOOD, 2016, 128 (22)
12345